Xencor Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $26.9
- Today's High:
- $28.185
- Open Price:
- $28.07
- 52W Low:
- $19.355
- 52W High:
- $38.2
- Prev. Close:
- $28.03
- Volume:
- 382775
Company Statistics
- Market Cap.:
- $1.68 billion
- Book Value:
- 12.125
- Revenue TTM:
- $164.58 million
- Operating Margin TTM:
- -49.19%
- Gross Profit TTM:
- $-34984000
- Profit Margin:
- -33.53%
- Return on Assets TTM:
- -6.01%
- Return on Equity TTM:
- -7.55%
Company Profile
Xencor Inc had its IPO on 2013-12-03 under the ticker symbol XNCR.
The company operates in the Healthcare sector and Biotechnology industry. Xencor Inc has a staff strength of 281 employees.
Stock update
Shares of Xencor Inc opened at $28.07 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $26.9 - $28.19, and closed at $27.4.
This is a -2.25% slip from the previous day's closing price.
A total volume of 382,775 shares were traded at the close of the day’s session.
In the last one week, shares of Xencor Inc have increased by +2.01%.
Xencor Inc's Key Ratios
Xencor Inc has a market cap of $1.68 billion, indicating a price to book ratio of 2.3648 and a price to sales ratio of 5.567.
In the last 12-months Xencor Inc’s revenue was $164.58 million with a gross profit of $-34984000 and an EBITDA of $-72164000. The EBITDA ratio measures Xencor Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Xencor Inc’s operating margin was -49.19% while its return on assets stood at -6.01% with a return of equity of -7.55%.
In Q4, Xencor Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 86%.
Xencor Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.94 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Xencor Inc’s profitability.
Xencor Inc stock is trading at a EV to sales ratio of 3.8786 and a EV to EBITDA ratio of 19.0335. Its price to sales ratio in the trailing 12-months stood at 5.567.
Xencor Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $846.27 million
- Total Liabilities
- $63.84 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $5.99 million
- Dividend Payout Ratio
- 0%
Xencor Inc ended 2023 with $846.27 million in total assets and $0 in total liabilities. Its intangible assets were valued at $846.27 million while shareholder equity stood at $727.50 million.
Xencor Inc ended 2023 with $0 in deferred long-term liabilities, $63.84 million in other current liabilities, 601000.00 in common stock, $-338285000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $53.94 million and cash and short-term investments were $580.63 million. The company’s total short-term debt was $4,708,000 while long-term debt stood at $0.
Xencor Inc’s total current assets stands at $675.34 million while long-term investments were $58.21 million and short-term investments were $526.69 million. Its net receivables were $29.00 million compared to accounts payable of $10.09 million and inventory worth $0.
In 2023, Xencor Inc's operating cash flow was $0 while its capital expenditure stood at $5.99 million.
Comparatively, Xencor Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $27.4
- 52-Week High
- $38.2
- 52-Week Low
- $19.355
- Analyst Target Price
- $44.85
Xencor Inc stock is currently trading at $27.4 per share. It touched a 52-week high of $38.2 and a 52-week low of $38.2. Analysts tracking the stock have a 12-month average target price of $44.85.
Its 50-day moving average was $31.69 and 200-day moving average was $28.87 The short ratio stood at 12.54 indicating a short percent outstanding of 0%.
Around 88% of the company’s stock are held by insiders while 10529.8% are held by institutions.
Frequently Asked Questions About Xencor Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer’s disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.